Diabecell, encapsulated insulin-producing cells to be implanted into the abdomen of patients developed by Living Cell Technologies Limited, has been granted approval for phase 2 human trials in New Zealand.
Edoxaban, an investigative once-daily oral factor Xa inhibitor to arrest blood clotting, has been submitted for approval in Japan by Daiichi Sankyo.
TachoSil, an absorbable fibrin sealant patch for use in cardiovascular surgery to prevent mild and moderate bleeding from small blood vessels, has been approved in US.
Parexel International Corporation, a leading global biopharmaceutical services provider, has introduced a new web-based technology platform for late phase clinical research for the biopharmaceutical industry.
Inhaled ciprofloxacin for the treatment of bronchiectasis is currently in clinical trails, Aradigm announced.
The generic drugs market in the world's biggest pharmaceuticals market US is anticipated to grow at a CAGR of around 9% during 2010-2012 even as India companies line up to grab a considerable share of the business.
Access Pharma is currently developing cobalamin-based oral insulin to treat type 2 diabetes, the company announced.